Innovative Technology Saluda Medical’s Evoke System employs advanced ECAP-controlled, closed-loop neuromodulation technology, allowing for highly personalized and adaptive pain management. This innovative approach offers a compelling value proposition for clinicians seeking more precise and effective treatment solutions.

Strong Market Position Having recently gone public and raised $231 million in its IPO, Saluda Medical demonstrates significant growth and market confidence, positioning it as a key player in the neuromodulation and spinal cord stimulation sectors with expanding scalability potential.

Product Launch Momentum The recent launch of EVA sensing technology and full commercial rollout in the United States indicates ongoing product innovation and adoption, providing opportunities to partner with healthcare providers and distributors eager for cutting-edge therapies.

Strategic Leadership The appointment of a new CEO, Barry Regan, signals a strategic shift towards aggressive growth and market expansion, opening doors for tailored collaborations, especially in markets exploring neuromodulation solutions for complex pain conditions.

Expanding Clinical Evidence Participation in prominent industry events such as NANS 2025 and presentation of clinical data underscores the company’s commitment to evidentiary support, which can foster trust and facilitate sales with clinicians favoring proven, data-driven therapies.